Imperial College London
Portrait Picture

DrBlerinaAhmetaj-Shala

Faculty of Medicine, National Heart & Lung Institute

Advanced Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7351 8137b.ahmetaj

 
 
//

Location

 

Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mohamed:2016:10.1007/s12265-016-9684-2,
author = {Mohamed, NA and Ahmetaj-Shala, B and Duluc, L and Mackenzie, LS and Kirkby, NS and Reed, DM and Lickiss, PD and Davies, RP and Freeman, GR and Wojciak-Stothard, B and Chester, AH and El-Sherbiny, IM and Mitchell, JA and Yacoub, MH},
doi = {10.1007/s12265-016-9684-2},
journal = {Journal of Cardiovascular Translational Research},
pages = {162--164},
title = {A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension.},
url = {http://dx.doi.org/10.1007/s12265-016-9684-2},
volume = {9},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effects have hampered the clinical use of NO in PAH. In an attempt to circumvent these major limitations, we have developed a new NO-nanomedicine formulation. The formulation was based on hydrogel-like polymeric composite NO-releasing nanoparticles (NO-RP). The kinetics of NO release from the NO-RP showed a peak at about 120 min followed by a sustained release for over 8 h. The NO-RP did not affect the viability or inflammation responses of endothelial cells. The NO-RP produced concentration-dependent relaxations of pulmonary arteries in mice with PAH induced by hypoxia. In conclusion, NO-RP drugs could considerably enhance the therapeutic potential of NO therapy for PAH.
AU  - Mohamed,NA
AU  - Ahmetaj-Shala,B
AU  - Duluc,L
AU  - Mackenzie,LS
AU  - Kirkby,NS
AU  - Reed,DM
AU  - Lickiss,PD
AU  - Davies,RP
AU  - Freeman,GR
AU  - Wojciak-Stothard,B
AU  - Chester,AH
AU  - El-Sherbiny,IM
AU  - Mitchell,JA
AU  - Yacoub,MH
DO  - 10.1007/s12265-016-9684-2
EP  - 164
PY  - 2016///
SN  - 1937-5395
SP  - 162
TI  - A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension.
T2  - Journal of Cardiovascular Translational Research
UR  - http://dx.doi.org/10.1007/s12265-016-9684-2
UR  - http://hdl.handle.net/10044/1/31744
VL  - 9
ER  -
Download